首页> 外文期刊>Experimental and clinical transplantation >Conversion From Steroid to Everolimus in Maintenance Kidney Transplant Recipients With Posttransplant Diabetes Mellitus
【24h】

Conversion From Steroid to Everolimus in Maintenance Kidney Transplant Recipients With Posttransplant Diabetes Mellitus

机译:从类固醇到依维莫司在维持肾脏移植受者中的转化。

获取原文
           

摘要

Objectives: Although steroid withdrawal has been attempted to ameliorate various complications in kidney transplant recipients, a steroid-sparing strategy has more frequently led to acute rejection. We investigated the use of everolimus to safely overcome steroid withdrawal in kidney transplant recipients with posttransplant diabetes mellitus under maintenance immunosuppressive therapy. Materials and Methods: A total of 75 de novo consecutive kidney transplant recipients received conventional immunosuppressive therapy comprising tacrolimus (trough level of 5 ng/mL), mycophenolate mofetil (1000 mg), and methylprednisolone (4 mg). Patients with posttransplant diabetes mellitus under?-went simultaneous everolimus administration (trough level of 3-5 ng/mL) and steroid withdrawal at 1 to 15 months after transplant. Graft outcomes were compared between the everolimus and steroid groups. In the everolimus group, renal function and hemoglobin A1c levels at 12 months after admin?-istration were compared with values before everolimus administration. Results: The mean posttransplant follow-up period in the everolimus (n = 25) and steroid (n = 50) groups was 672 and 747 days, respectively. All grafts survived in both groups, and biopsy-proven acute rejection rates did not significantly differ between the groups (16% vs 12%; P = .72). Furthermore, no acute rejection occurred after everolimus administration. In the everolimus group, hemoglobin A1c significantly declined at 9 months after everolimus administration (6.94% vs 6.53%; P = .047). In addition, both serum creatinine levels and estimated glomerular filtration rates in the everolimus group were stable for 12 months after everolimus administration. Conclusions: Steroid withdrawal using everolimus as maintenance immunosuppressive therapy for kidney transplant recipients may safely ameliorate post?-transplant diabetes mellitus, achieve better glycemic control, and maintain stable renal function.
机译:目的:尽管已尝试戒断激素以减轻肾移植受者的各种并发症,但降低激素的策略更经常导致急性排斥反应。我们研究了依维莫司在维持免疫抑制治疗下,在移植后糖尿病的肾移植受者中安全地克服类固醇激素撤药的使用。材料和方法:总共75例从头开始的连续肾脏移植受者接受了常规的免疫抑制疗法,包括他克莫司(谷水平5 ng / mL),霉酚酸酯(1000 mg)和甲基泼尼松龙(4 mg)。移植后糖尿病患者在移植后1至15个月同时接受依维莫司治疗(谷水平为3-5 ng / mL)和类固醇戒断。比较了依维莫司和类固醇组的移植结果。在依维莫司组中,将给药后12个月的肾功能和血红蛋白A1c水平与依维莫司给药前的值进行比较。结果:依维莫司组(n = 25)和类固醇组(n = 50)的平均移植后随访期分别为672天和747天。两组均存活,并且活检证实的急性排斥率在两组之间无显着差异(16%vs 12%; P = 0.72)。此外,依维莫司给药后未发生急性排斥反应。在依维莫司组中,依维莫司给药后9个月血红蛋白A1c显着下降(6.94%对6.53%; P = .047)。另外,依维莫司组的血清肌酐水平和估计的肾小球滤过率在依维莫司给药后12个月内保持稳定。结论:使用依维莫司作为维持免疫抑制治疗的肾移植受者类固醇戒断可以安全地改善移植后糖尿病,实现更好的血糖控制,并维持稳定的肾功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号